Peter Kim: How do I love thee...

[Anonymous]

...let me count the ways...

1. No black box warning on Vioxx. Just let it go.
2. <0.1x return on Rosetta. for $620 million, and sell it for $50 million.
3. MK-524a and b, and MK-859 in phase III for almost your entire tenure at MRL
4. Investing and re-investing and re-investing in cardiovascular medicine with failure after failure.
5. No return on $400 million purchase on GlycoFi with total failure of MK-7528
6. Being forced to "reverse merger" with SCH to rejuvenate your pipeline - only to have the lead program fail.
7. Your skillful management techniques of isolation and fragmentation
8. AND THE LATEST...no return on Sirna after $1.1 billion


There are so many fond memories, I may have forgotten a few. Perhaps my friends can help me reminisce...

 

[Anonymous]

Perhaps a more experienced research director would have helped, but take a look around - NO major drug company in the past 10 years has discovered any major new medicines. It's an industry wide problem. The R&D heads of every drug company look bad because there are no low hanging fruit anymore.

Though, I'm not surprised by the simplistic scapegoating given the contents of the poll. It's definitely the same simplistic thinking reflective of tea bagging Bachmann-loving, Faux News watching SHEEP.

 

[Anonymous]

Perhaps a more experienced research director would have helped, but take a look around - NO major drug company in the past 10 years has discovered any major new medicines. It's an industry wide problem. The R&D heads of every drug company look bad because there are no low hanging fruit anymore.

Though, I'm not surprised by the simplistic scapegoating given the contents of the poll. It's definitely the same simplistic thinking reflective of tea bagging Bachmann-loving, Faux News watching SHEEP.

Your excuse and excuse and excuse reasoning doesn't hold water. Plenty of fancy new drugs are being discovered, just go to the FDA web site and read the yearly summary. Even Schering-Plough discovers new drugs, most recently boceprevir. The same HCV program at legacy Merck failed miserably under Peter Kim. At any rate you are admitting that Merck is no better than average Joe Pharma nowadays. Very true! However, you forgot that Merck was the top notch company a little more than a decade ago, and Peter Kim was hired to keep it so. Sure he may not be the only culprit, the CEO and the Board were at fault as well. But Peter is responsible for the pipeline and he was given plenty of cash to keep it top of the line. Our pipeline is shit and you want to blame the competition!!!! Pea brain!

He got 10 years making millions upon millions, don't you think it's enough???? Peter and the whole Merck leadership, including their running dogs should all be fired for making Merck no better than average Joe Pharma. I am a stock holder and I am mad as hell.

 

[Anonymous]

Perhaps a more experienced research director would have helped, but take a look around - NO major drug company in the past 10 years has discovered any major new medicines. It's an industry wide problem. The R&D heads of every drug company look bad because there are no low hanging fruit anymore.

Though, I'm not surprised by the simplistic scapegoating given the contents of the poll. It's definitely the same simplistic thinking reflective of tea bagging Bachmann-loving, Faux News watching SHEEP.

Maybe we should stop trying to build desktops when consumers want hand-held wireless.